On a cold, dreary Ontario morning a young secretary takes as her breakfast one cup of black coffee, two slices of toast and one 250 mg capsule of vitamin C. A few hours earlier, a young Nova Scotian bank clerk, in response to the onset of listlessness and a bout of sneezing, hastily swallows five 250 mg capsules of ascorbic acid in the belief that this will ward off an impending common cold. In a small prairie town a young unemployed man with a six-year history of schizophrenia, characterized by numerous admissions to the provincial mental hospital, is watched over by an anxious and concerned mother who supervises her son as he begins to ingest the day's prescription of 30,000 mg of vitamin C and 30,000 mg of vitamin B-3 (nicotinic acid). Conventional psychotherapy, tranquillizers and ECT have been largely unsuccessful in checking the progressive downward swing in his overall personality functioning. Perhaps the vitamins will be helpful. Besides, the megavitamin treatment has been sanctioned by the family physician and a specialist in psychiatry. These are three of the many ways in which vitamins are being used today.
The use of vitamins in rather massive dosages in the treatment of schizophrenia is an outcome of work done over twenty years ago in Saskatchewan by Dr. A. Hoffer and his colleagues. Hoffer, Osmond and Smythies, in a paper entitled "Schizophrenia: A new Approach", developed a unifying hypothesis designed to integrate the Can. Psychiatr. Assoc. J. Vol. 20 (1975) 97 then accepted biochemical, clinical and psychological factors associated with schizophrenia. Nearly forty years earlier, Cannon published his discovery of the role of norepinephrine and epinephrine in the adaptation to 'stress' -a notion that abnormal mental states are the result of faulty adaptation to overwhelming environmental stimulation. Cannon's idea was developed further by Osmond and Smythies who formulated the hypothesis that schizophrenia is the outcome of stress-induced anxiety and a failure of metabolism resulting in highly toxic mescaline-like (M) compounds.
In 1954, Hoffer, Osmond and Smythies proposed that adrenochrome, an oxidation product of epinephrine with psychotoxic properties, was the "M" substance suggested earlier by Osmond and Smythies. Its production was believed to be the result of the increased serum phenolase oxidase activity in schizophrenic patients. The rationale to give nicotinic acid in a clinical trial was based on the fact that epinephrine is synthesized in vivo from norepinephrine by N-methylation. Epinephrine but not norepinephrine can be oxidized in vivo to adrenochrome and adrenolutin. Following the administration of these two compounds to normal subjects, Hoffer and Osmond observed a psychological change which appeared to mimic the functional schizophrenic reaction. It was then postulated that both adrenochrome and adrenolutin might be formed endogenously by patients suffering from schizophrenia. Since nicotinic acid is a Vol. 20, No.2 strong methyl group acceptor, it could conceivably compete for methyl groups and thus prevent the conversion of norepinephrine to epinephrine. Any diminution of epinephrine would correspondingly decrease the quantities of adrenochrome and adrenolutin formed, and therefore should be helpful in reducing the perceptual distortions and other symptoms of a person suffering from schizophrenia.
The theoretical biochemical postulates offered in 1952 have now been translated into clinical treatment in the administration of massive dosages of niacin for the treatment of schizophrenia. Megavitamin therapy now also includes vitamin B-3, vitamin B-6 (pyridoxine), pantothenic acid, vitamin B-12, folic acid, vitamin C, minerals, hormones and high protein-low carbohydrate diets. These may be used in conjunction with various neuroleptic and antidepressant drugs as indicated.
The case for megavitamins was given considerable credibility in 1968 when the innovative ideas of Professor Linus Pauling were added to consolidate the theoretical position. Pauling coined the term 'Orthomolecular Psychiatric Therapy' and defined it as "the treatment of mental disease by the provision of the optimum molecular environment for the mind, especially the optimum concentration of substances nor: mally present in the human body." He argued that some forms of mental illness might be due to vitamin deficiencies occurring even on ordinarily adequate diets, and that such deficiencies could be due to a genetically idiosyncratic need the individual might have for exceptionally large doses of vitamins. Not only did the evolution from megavitamin to orthomolecular psychiatry involve a much more comprehensive treatment regime for schizophrenia, but this was also parallelled by a change in the underlying biochemical rationale for the use of B-3 in schizophrenia. Formerly, vitamin B-3 was thought to act as a methyl group acceptor which reduced the formation of a postulated endogenous psychotogen. However, schizophrenia is now viewed as an incipient form of cerebral pellagra based upon individually idiosyncratic needs for unusually high quantities of the vitamin. It is postulated that there is a biochemical block between the substrate vitamin B-3 and its incorporation into the co-enzyme nicotinamide adenine dinucleotide. Orthomolecular psychiatric therapy has now evolved into a science of nutrition in relation to both mental and physical health. Schizophrenia is clearly conceptualized as having a metabolic origin. Arthritis, alcoholism, childhood autism and hyperlipidemia are some other pathological conditions which are said to respond favourably to orthomolecular therapy.
There is an increasing and potentially bitter controversy raging in the United States, and to a lesser extent in Canada, between the proponents of orthomolecular psychiatry and the conventional psychiatric and medical establishment over the biochemical rationale and clinical efficacy of megavitamin therapy. A number of general practitioners and psychiatrists have become advocates of orthomolecular therapy, but generally the medical profession has remained somewhat aloof. However, this has not been the case with the lay public who have responded in large numbers and in many instances have launched severe and bitter criticisms of the psychiatric and medical profession for what has been perceived as their indifferent, and contemptuously condescending attitude towards advocates of megavitamin therapy. The emergence of such organizations as The American Schizophrenia Association, The Huxley Society, Schizophrenics Anonymous, and the Canadian Schizophrenic Foundation attest to the growing concern of a large segment of the public over the megavitamin issue.
The controversy embraces serious conceptual, operational, and methodological differences and no accommodating compromise or elucidating dialogue between the two groups is apparent. Orthomolecular practitioners for their part are critical of conventional psychiatrists for their obsession with methodology and their unwillingness to conduct simple, open megavitamin trials. Two of the more basic criticisms, one economic, the other philosophical, have been offered by orthomolecular spokesmen to explain the almost negligible interest in in megavitamin therapy among non-orthomolecular practitioners. The use of megavitamins does not bring a profitable commercial advantage to the medical-pharmaceutical complex. Secondly, many conventional psychiatrists subscribe rather dogmatically to a psychogenic etiology of schizophrenia. A recent book entitled Orthomolecular Psychiatry, edited by Hawkins and Pauling, outlines rather comprehensively this orthomolecular position. The book includes both theoretical and clinical material written by some of their most outstanding theoreticians and practitioners.
Criticisms of the orthomolecular movement by conventional psychiatry are numerous and have been summarized rather succinctly by the Task Force Report of the American Psychiatric Association. The Research Council of the Canadian Psychiatric Association has also issued a position paper on megavitamin therapy. Briefly, critics of orthomolecular psychiatry strongly object to the continuing barrage of dramatic, striking and largely unsubstantiated statements and publications concerning the clinical efficacy of megavitamin therapy when the theoretical and biochemical bases for the treatment are open to serious question and since various chemical and psychological tests used for diagnostic assessment and to measure treatment response have been found to be lacking in both specificity and reliability.
Attempts to precisely replicate orthomolecular studies have been difficult or impossible. In one of the most widely publicized and respected studies-that of Wittenborn and colleagues-s-a controlled, double-blind trial designed to determine the efficacy of niacin as a supplement in the treatment of schizophrenic patients, failed to show a therapeutic advantage for the supplemental use of niacin over the course of two years. The most far reaching, exhaustive and thorough-going study into the therapeutic potentiality of megavitamins in schizophrenia, carried out by Lehmann and Ban-a study begun in 1966 and sponsored by the Canadian Mental Health Association-was also unable to confirm the overall general efficacy of niacin in the treatment of schizophrenia. Progress Report II of this study appears in this issue.
In some cases there has been an honest difference of emphasis regarding conclusions which has led to unnecessary controversy. A case in point is Pauling's criticism of Greenbaum's controlled study involving the use of niacinamide in the treatment of childhood schizophrenia. Fiftyseven children were separated into three groups; those given niacinamide, those given niacinamide plus a tranquillizer and those given a placebo. Greenbaum reported, "no significant difference attributable to niacinamide", although there was improvement in the average score in the niacinamide group of four units, and 2.6 units for the placebo group. Pauling argues that Greenbaum's "statement is strongly misleading", and that it is more likely that niacinamide has an effect rather than no effect. Here the two investigators are obviously talking about two different things; one, the lack of significance with respect to improvement, the other, that there is an improvement which might have become statistically significant if a larger number of subjects were used.
What conclusions can be drawn from such a difficult and controversial subject, after considerable thought, and a perusal of the relevant literature? First, it should be pointed out that there are several areas of controversy in medicine and medical research in which there are honest basic differences of views concerning theoretical positions, clinical treatment, and all manner of research data from which diametrically opposed inferences are drawn. What is unique and potentially dangerous here is the interposing of a confused and often poorlyinformed lay public between the conventionalist and the orthomolecular group. This group consists of suffering patients, sympathetic friends, discouraged parents and an over-zealous news media. A controversy that could not be resolved and contained in the research laboratory, the hospital or in the halls of international science now moves ominously into the sociopolitical arena. Conclusions are at best tentative and Vol. 20, No.2 sometimes presumptuous as they presuppose that the right questions are being asked or the most appropriate and potentially most fruitful hypotheses have been formulated. A few summarizing statements on the subject will be offered. It is hoped that they will provoke clear-headed and unbiased thinking and discussion as first steps towards an honest, humane dialogue between the opposing camps.
First, nicotinic acid or nicotinamide when used as an adjunct to conventional . therapies such as barbiturates and electroconvulsive treatment, as reported earlier by Hoffer, may have a beneficial effect in the treatment of some patients suffering from acute, early schizophrenia. The observed beneficial effect could reflect the presence of a small homogeneous subgroup of schizophrenic people out of an overall heterogeneous pool whose genetically determined biochemical defect may be manifested as a vitamin or co-enzyme deficiency. As far as is known, no attempt has been made to duplicate these earlier studies of Hoffer.
Second, megavitamin therapy has not been demonstrated to be generally efficacious in the treatment of the vast majority of chronic schizophrenic patients. It is generally safe and non-toxic, but adverse side effects (some serious) may be provoked by using extremely high dosages of these vitamin drugs.
Third, orthomolecular psychiatry as defined by Pauling has now superseded megavitamin therapy. This newly-evolved treatment approach which focuses on the biology of nutrition in relation to mental and physical health, must be considered at the present time to be highly experimental, as its general usefulness in the treatment of schizophrenia await further definition and evaluation.
Fourth, methodological problems are enormous. Extreme difficulty is involved in replicating the reported positive therapeutic results with one variable only, namely nicotinic acid. The replication of studies involving multiple component variables, appreciable quantitive variations in the use of anyone variable, and an empirical decision with respect to the inclusion or exclusion of a given variable, presents an almost impossible task.
Fifth, Schizophrenics Anonymous and similar self-help groups which are outgrowths of orthomolecular psychiatry, and which serve to reduce loneliness, alienation, and shame-guilt in Its members by providing community day-care centres, job placements, and other social amenities, have useful psychological and social value.
Orthomolecular psychiatrists should be invited to return to the forum of conventional psychiatry in order that they might be given audience. Their articles should be submitted to conventional journals and should be received with the same enthusiasm and cordiality as other submissions, provided the general criteria of the journal are met. Further, despite uniformly unsuccessful attempts to replicate the impressive therapeutic results reported by orthomolecular therapists, conventional psychiatric investigators and therapists must remain open minded and suspend judgement in order to further critical research in this controversial area. W.T.B .
. The evils ofcontroversy are transitory, while its benefits are permanent.
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